newsfilter
← Latest News
PR Newswire·

Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine...